Uniqure NV (QURE) Peer Comparison
$44.34
$-0.53
(-1.17%)
As on 04-Sep-2026 13:37EDT
Market cap
$3,380 Mln
Revenue (TTM)
$19 Mln
P/E Ratio
--
P/B Ratio
10.6
Div. Yield
0 %
Edit
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
3,380 | 9,057 | 2,480 | 323 | 2,704 |
Revenue ($ Mln) |
19 | 2,100 | -- | 19 | 4 |
Net Profit ($ Mln) |
-252.21 | 409.32 | -171.57 | -42.32 | -668.19 |
Net Margin (%) |
-1,350.73 | 19.49 | -- | -228.38 | -14,938.37 |
RoE (%) |
-96.46 | 11.47 | -59.98 | -65.71 | -335.54 |
Price to Earnings |
-- | 22.49 | -- | -- | -- |
Price-To-Book |
10.60 | 2.67 | 7.40 | 3.51 | 15.46 |
Cashflow ($ Mln)
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-177.96 | 654.33 | -137.07 | -52.79 | -102.68 |
|
Cash Flow from Investing Activities
|
-321.62 | -305.28 | -0.16 | -1.02 | -109.13 |
|
Cash from Financing Activities
|
415.40 | -178.98 | 160.61 | -1.84 | 269.48 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-50.07 | 8.01 | -64.99 | -44.48 | -361.72 |
|
ROE (%)
|
-96.46 | 11.47 | -59.98 | -65.71 | -335.54 |
|
ROA (%)
|
-29.77 | 6.10 | -38.54 | -17.96 | -184.51 |
|
EBIT Margin (%)
|
-1,047.15 | 23.80 | -- | -229.99 | -15,198.77 |
|
Net Margin (%)
|
-1,350.73 | 19.49 | -- | -228.38 | -14,938.37 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | -- | 0.00 | -0.02 |
Growth Ratios
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
30.24 | 2.96 | -- | 12.40 | 93.72 |
|
EBIT Growth (%)
|
-44.77 | -4.99 | 1.05 | -13.38 | -530.01 |
|
Net Profit Growth (%)
|
-26.74 | 9.62 | -1.94 | -6.67 | -459.61 |
|
EPS Growth (%)
|
-4.52 | 14.23 | 15.07 | 6.83 | -316.60 |
|
Book Value Growth (%)
|
6,797.66 | 0.56 | 31.10 | -3.20 | -33.14 |
Valuation Ratios
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-6.92 | 21.99 | -10.30 | -5.14 | -1.38 |
|
Price / Book Value
|
6.92 | 2.67 | 6.67 | 3.59 | 4.09 |
|
Dividend Yield (%)
|
-- | 0.82 | -- | -- | -- |
|
EV/EBITDA
|
-11.07 | 13.06 | -8.76 | -3.13 | -0.99 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.15 | 0.48 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.00 | 0.00 | 0.06 | 0.02 |
|
Current Ratio
|
10.01 | 2.85 | 11.94 | 3.49 | 8.58 |
|
Quick Ratio
|
10.01 | 2.31 | 11.94 | 3.49 | 8.58 |
|
Interest Coverage
|
-3.11 | 12.71 | -1,045.90 | -45.75 | -334,090.00 |
Operating Efficiency Ratios
| Uniqure NV (QURE) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | ATAI Life Sciences BV (ATAI) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
30.94 | 19.00 | -- | 10.03 | 14.46 |
|
Asset Turnover
|
0.02 | 0.31 | 0.00 | 0.08 | 0.01 |
|
Receivable days
|
133.23 | 75.29 | -- | 96.49 | 704.55 |
|
Inventory Days
|
0.00 | 132.91 | -- | -- | -- |
|
Payable days
|
1,342.82 | 35.66 | -- | 25.78 | 1,357.42 |
|
Cash Conversion Cycle
|
-1,209.59 | 172.54 | -- | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
